Clinical Trial Update: A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) [Phase 2]

View source ↗

Summary

The Phase 2 trial MK-5890-003 evaluating boserolimab with pembrolizumab and chemotherapy for early triple-negative breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Boserolimab (boserolimab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Early Triple Negative Breast Cancer | Phase 2 | Status: WITHDRAWN